RT Journal Article
SR Electronic
T1 CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.26.21264023
DO 10.1101/2021.09.26.21264023
A1 Baker, David
A1 MacDougall, Amy
A1 Kang, Angray S.
A1 Schmierer, Klaus
A1 Giovannoni, Gavin
A1 Dobson, Ruth
YR 2021
UL http://medrxiv.org/content/early/2021/09/27/2021.09.26.21264023.abstract
AB Background CD20 depletion is a highly-effective treatment for relapsing multiple sclerosis that maintains B cells at low levels through six monthly dosing of 600mg ocrelizumab. This dosing schedule is associated with inhibition of seroconversion following SARS-CoV-2 vaccination, in contrast to the high levels of seroconversion following treatment with alemtuzumab and cladribine tablets. A number of emerging reports suggest that repopulation of 1-3% B cells facilitates seroconversion after CD20-depletion. The frequency of this occurring following repeated ocrelizumab treatment, after other DMT, and after treatment cessation is largely unknown.Methods Relapse data, lymphocyte and CD19 B cell numbers were extracted from phase II ocrelizumab extension study (NCT00676715) data supplied by the manufacturer via the Vivli Inc, trial data-request portal. Repopulation data of oral cladribine from the phase III CLARITY study (NCT00213135) was supplied by the European Medicines Agency; and the alemtuzumab phase III CARE-MS I (NCT00530348) and CARE-MS II (NCT00548405) trial data were supplied by the manufacturer via the clinicalstudydatarequest.com portal.Results Only 3-5% of people with MS exhibit 1% B cells at 6 months after the last infusion following 3-4 cycles of ocrelizumab, compared to 50-55% at 9 months, and 85-90% at 12 months. During this time relapses occurred at consistent disease breakthrough rates compared to people during standard therapy. In contrast most people (90-100%) exhibited more than 1% B cells during treatment with either cladribine or alemtuzumab.Conclusions Few people repopulate peripheral B cells with standard ocrelizumab dosing, however an extending the dosing interval by 3-6 months may allow many more people to potentially seroconvert in the relative absence of excess relapse-activity. Most people demonstrate B cell repletion within 3 months of the last treatment of alemtuzumab and cladribine. This may help protect against severe COVID-19.Competing Interest StatementDB, KS, GG RB, have received compensation for consultancy/educational activity from Roche/Genentech, Merck, and/or Sanofi/Genzyme who manufacture COVID-19 and MS drugs discussed in this study. These were not involved in the content or the decision to publish. AM, AK have nothing relevant to declare. Although considered irrelevant DB, KS, GG, RB have received compensation for consultancy/educational activity from all companies manufacturing licenced disease modifying agents in the MS space.Clinical TrialNCT00676715, NCT00213135, NCT00530348, NCT00548405Funding StatementThis study received no fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Anonymised ocrelizumab and alemtuzumab data was provided by the trial sponsors following an independent panel review, that includes bioethics analysis, at clinincaltrialsdatarequest.com of the data analysis plans. Anonymized cladribine trial data was supplied by the European Medicines Agency, drug regulators. This post-hoc analysis was not subject to further ethical review. However, the original trial protocols for data collection were reviewed and approved by the local review boards or ethics committees at each study centre for the ocrelizumab phase II trial [NCT00676715. 79 Centres], the phase III cladribine tablet study [NCT00213135. 155 centres] and the alemtuzumab [NCT00530348. 101 medical centres and NCT00548405. 194 Medical centres], phase III trials [Kappos et al. 2011, Giovannoni et al. 2010, Cohen et al. 2012, Coles et al. 2012]. The studies were performed in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent [Kappos et al. 2011, Giovannoni et al. 2010, Cohen et al. 2012, Coles et al. 2012]. These are multi-centre randomised controlled international trials the details of the trial centres can be found in clinicaltrials.gov. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380:1819-1828 Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012; 380:1829-1839 Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011; 378:1779-1787. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, et al. CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010; 362:416-26. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll trial data is available via the Vivli.Inc and Clinicalstudydatarequest.com portals which are provided under agreement with the data providers.